Back to search results
NCT05346809

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatment
Divaya Bhutani
~8 participants
Updated 2026-07-23 on ClinicalTrials.gov
What's tested:IsatuximabStandard Procedures

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in the total lymphocyte count
Measured over Day 30

Conditions

Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
Relapsed Hodgkin's Disease, Adult

Explore related trials

Diffuse Large B-Cell LymphomaHodgkin's GranulomaIndolent B-cell LymphomaMantle Cell LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaMultiple Myeloma

NCT05346809

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Columbia University

    New York, New Yorkno site contact published

  • Karmanos Cancer Institute

    Detroit, Michiganno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Divaya Bhutani · PRINCIPAL_INVESTIGATOR · Columbia University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Relapsed/Refractory Diffuse large B cell lymphoma
Relapsed/Refractory indolent or relapsed/refractory transformed indolent B cell lymphomas as consolidation after second line therapy
Mantle Cell lymphoma as consolidation after first-line therapy
Peripheral T cell lymphoma as consolidation after first-line therapy or at relapse or primary refractory disease 2. Patients undergoing first ASCT will be eligible for the study. 3. Any prior therapy for the malignancy except CD38 antibody within the last 12 months is allowed. 4. Age ≥18 years 5. Life expectancy of greater than 6 months.

What this trial measures

  • Change in the total lymphocyte countDay 30

    Change in total lymphocyte count measured from blood sample